Ypsomed (SIX:YPSN) announced today that it developed a new autoinjector platform for liquid medications with volumes between 1.5 mL and 5.5 mL.
Burgdorf, Switzerland-based Ypsomed built the YpsoMate 5.5 autoinjector on the established technology of the YpsoMate 2.25 Pro. The latest addition to the YpsoMate portfolio enables self-administration for larger-volume medications. These medications may treat cancer, as well as rare and autoimmune diseases.
Self-medication makes daily life easier for people with chronic diseases and reduces healthcare burdens, Ypsomed said in a news release. The company’s self-injection system with a pre-filled syringe allows patients to treat themselves at home instead of visiting a medical facility. Larger dosing volumes can also reduce the number of injections they require.
“YpsoMate 5.5 represents the newest member of the YpsoMate autoinjector family and expands the application range of current autoinjectors by enabling the administration of larger volumes in the range of 2.0 to 5.5 ml from a pre-filled syringe,” said Ulrike Bauer, chief business officer for delivery systems at Ypsomed. “We are setting a new standard for self-management of chronic diseases.”
The YpsoMate 5.5 autoinjector features a two-step handling process for simplicity and safety. Removing the cap and pushing against the skin triggers the injection process automatically. The device also comes with a handgrip to allow comfortable handling and a stable hand position. It emits a continuous visual and audible signal to offer control over the injection process.
Ypsomed said its autoinjector also features an integrated, pre-filled syringe developed in collaboration with Schott Pharma. The joint development resulted in the syriQ BioPure 5.5 mL, a large-volume, pre-fillable syringe with an integrated needle.